SAN FRANCISCO, CA and NORTHBROOK, IL--(Marketwire - February 25, 2013) - Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (TSE: 4503), announced that the companies are providing additional support to the Chronic Disease Fund (CDF). CDF uses charitable donations to help eligible men with metastatic castration resistant prostate cancer that need financial assistance paying their out-of-pocket expenses, including co-pays or co-insurance. CDF is an independent, non-profit organization that provides financial assistance to help eligible patients obtain prescription medications. Independent of Astellas and Medivation, CDF determines how to distribute donations and evaluate patient eligibility.
"Astellas and Medivation are committed to helping patients access medicines their physicians believe are necessary. Organizations like CDF provide an invaluable resource to patients in need and we applaud their efforts," said Mark Reisenauer, Vice President, Astellas Oncology.
"We are proud to support non-profit charitable organizations, such as the CDF, that are striving to provide the greatest level of access, care and assistance to patients to help them obtain the medicines that they need," said Melissa Abel, Vice President at Medivation, Inc.
Information about programs established to help patients gain access to approved medications can be found at www.astellasaccess.com.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in oncology, and has several oncology products on the market and compounds in development. Astellas is proud to be an award recipient of the CEO Gold Standard Accreditation from the CEO Roundtable on Cancer. For more information on Astellas Pharma Inc., please visit our website at www.astellas.us.